Artificial Intelligence Enhances Pathologists' Interpretation of Tissue Samples

Recent research led by Karolinska Institutet, in collaboration with Yale University, has demonstrated that AI-assisted analysis significantly improves the accuracy and consistency of pathologists examining tissue samples from skin cancer tumors. The study involved 98 professionals, divided into two groups: experienced pathologists working independently and a mixed group aided by AI technology capable of quantifying tumor-infiltrating lymphocytes (TILs). TILs are immune cells that play a crucial role in diagnosing and predicting the prognosis of malignant melanoma, with higher TIL levels generally indicating a better outlook.

The AI-supported assessments outperformed traditional methods by providing highly reproducible results, regardless of the pathologist, and offering a more precise evaluation of disease severity. This accuracy is essential for guiding treatment decisions and improving patient outcomes. Notably, as the study was retrospective, the actual prognoses were already known, confirming the AI’s potential for future clinical application.

Understanding the severity of melanoma through tissue analysis is vital for determining the aggressiveness of treatment plans. The new AI tool's ability to accurately quantify TILs suggests it could become a valuable aid in clinical pathology, enhancing diagnostic reliability and helping tailor patient-specific therapies.

While the findings are promising, further studies are necessary before implementing this AI technology widely in clinical practice. As noted by study last author Balazs Acs, an associate professor at Karolinska, the integration of AI in pathology could revolutionize how tumor biomarkers like TILs are evaluated, ultimately supporting better treatment decisions.

This research is published in JAMA Network Open and underscores the potential of artificial intelligence to advance pathology and oncology diagnostics.

For more details, visit source.